Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

-- Filing regulatory submissions for important new agents and indications,

which now include sugammadex and asenapine from Organon.

"Schering-Plough now has four full years of accomplishments since we began this transformation," said Hassan. "In that time, we also brought a new culture to the company - focused on meeting the needs of our customers and patients, and founded on a commitment to quality, compliance and business integrity."

Hassan continued: "As we begin 2008, new challenges have emerged, especially the initial reaction to the ENHANCE trial. We and our joint venture partner Merck acted with integrity and good faith with respect to that trial. We stand behind VYTORIN and ZETIA, behind the validity of the science, and behind our commitment to doing what's right for patients and physicians."

The company noted that the pharmaceutical industry continues to be subject to ever-more critical scrutiny, where events can be mischaracterized and drive amplified reactions. The company believes that new scientific data are best presented and discussed at appropriate scientific and medical forums.

Medical experts and health advisory groups have long recognized high LDL cholesterol as a significant cardiovascular risk factor and recommended increasingly aggressive treatment of high cholesterol for certain patients. While it is too early to tell the impact of the ENHANCE trial results on the cholesterol business, lowering LDL cholesterol, along with healthy diet and lifestyle changes, remains the cornerstone of lipid treatment for patients at risk for heart disease. Clinical studies have demonstrated that VYTORIN lowered patients' LDL cholesterol more than rosuvastatin, atorvastatin and simvastatin at the doses studied and was able to get more patients to their goal.

OBS Integration

The company reviewed progress in the integration of OBS since the transaction closed in November 2007.

"The strategic soundness of th
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 RegeneCure ... the company,s  proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane ... A common problem encountered when patients have a ... sufficient bone volume to house the implant. Consequently there is ... substitute until the natural bone regenerates. The bone substitute material, ...
(Date:6/18/2013)... 2013 The "Bioinformatics Market By Sector (Molecular ... Tools & Data Analysis Services) & Application (Genomics, Proteomics & ... Market Drivers, Restraints, and Opportunities in North America ... and Rest of World. Browse ... 22 Figures 364 Pages and ...
(Date:6/18/2013)... 2013 Research and ... addition of the "Injectable Drug Delivery ... Devices [Disposables & Reusable, Fillable & Prefilled, ... Therapeutics [Diabetes & Oncology] - Global Forecasts ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ...
(Date:6/18/2013)... Inflamax Research Inc., a full service ... I-IV clinical trials, announced today that they will ... Technologies (NAET), a specialty air conditioning & environmental ... of mobile Environmental Exposure Chambers (EECs) used in ... , Inflamax Research has proprietary Next Generation ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... Perceptive Informatics , a leading eClinical solutions ... PRXL ), today unveiled the new release ... provides richer functionality to further streamline the clinical trial ... clinical trial sponsors to more efficiently manage the clinical ...
... films ever made on a device the size of an ... could make it possible to build radically smaller storage devices ... devices. There,s just one obstacle on the way. Nano-sized magnets ... hairs above absolute zero. Now a chemistry student at the ...
... March 28, 2011 DRIVE4COPD, the nation,s single largest ... named PRWeek,s Healthcare Campaign of the Year ... the most prestigious honors in the public relations industry, ... and education teams.  Boehringer Ingelheim Pharmaceuticals, Inc. is the ...
Cached Biology Technology:Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 2Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 3Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 4Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 5Heavy metals open path to high temperature nanomagnets 2DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 2DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 3DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 4
(Date:6/17/2013)... -- As mobile devices, smartphones and tablets become ... exponentially, and biometric authentication offers that security, according ... Insider ( www.heavyreading.com/mobile-networks ), a subscription research ... ). Biometrics Offer Promise for More ... on smartphones, analyzing the most lucrative verticals for ...
(Date:6/17/2013)... Entrepreneurship will be the topics under discussion during ... For the third consecutive year, this will be ... of experiences among members of Academy, Business, Educators, ... Confirmed speakers: Elisa Martn Garijo (IBM South Europe), ... and Mary O,Donovan (Hovione), among others. E3 Forum ...
(Date:6/16/2013)... 16, 2013)Male mice who were fed a high-fat diet ... who also had higher levels of body fat, a ... observed primarily in male offspring, despite their consumption of ... meeting of The Endocrine Society in San Francisco, Calif. ... affect metabolism and behavior of offspring dependent on the ...
Breaking Biology News(10 mins):Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 2Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 3'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Obese male mice father offspring with higher levels of body fat 2
... trials ever, researchers have found that an experimental vaccine ... of shingles--a painful nerve and skin infection--and dramatically reduced ... the disease. The findings appear in the June 2 ... The Shingles Prevention Study, conducted over 5 ½-years, was ...
... for pandemic influenza, a new study reports for the first ... spread from poultry to humans. The research appears in ... now available online. , Crossing the species barrier is an ... pandemic potential. Previous studies have focused on the ability of ...
... Two peas in a pod may not be so friendly when ... plant, once separated may treat the former conjoined twin as an ... looking at how plants determine who is a competitor when competing ... researcher in plant ecology. "There is no reason for roots to ...
Cached Biology News:Experimental shingles vaccine proves effective in nationwide study 2Experimental shingles vaccine proves effective in nationwide study 3Experimental shingles vaccine proves effective in nationwide study 4Less virulent strains of avian influenza can infect humans 2Plants discriminate between self and non self 2
Request Info...
... Chemicon's 3243 provides all the materials necessary ... use in CMV antigen studies analysis. Kit ... - (Catalog No. 5122) One bottle containing 220 ... Fixation Solution (5X) - (Catalog No. 5113) ...
... For use with suspension (non-adherent) ... uses vacuum filtration or centrifugation ... media. Compatible with 96-well ... in larger package sizes and ...
... The Zero Background/Kan Cloning ... with kanamycin resistance for selection ... vector utilizes positive selection to ... contains all of the reagents ...
Biology Products: